Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trump Meets With Two US FDA Commissioner Candidates; Third Still Lurking

Executive Summary

O'Neill and Srinivasan head to Trump Tower, but Gottlieb has not been eliminated.

You may also be interested in...



Gottlieb's Greatest Strength As US FDA Commissioner? Stability

Amid all the praise for his raising of FDA's profile and aggressive policy stances, Scott Gottlieb's most valuable contribution while in office may have been leaving the agency fundamentally unchanged, an important lesson for incoming Acting Commissioner Norman Sharpless.

Gottlieb Unlikely To Make Major Changes Right Away, Former Official Says

New US FDA commissioners have a lot of housekeeping to do before they can get to the fun stuff, according to former associate commissioner Wayne Pines.

Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process

Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.

Related Content

Topics

UsernamePublicRestriction

Register

PS119825

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel